title: A novel cytostatic form of autophagy in sensitization of non-small cell lung cancer cells to radiation by vitamin D and the vitamin D analog, EB 1089.
abstract: The standard of care for unresectable lung cancer is chemoradiation. However, therapeutic options are limited and patients are rarely cured. We have previously shown that vitamin D and vitamin D analogs such as EB 1089 can enhance the response to radiation in breast cancer through the promotion of a cytotoxic form of autophagy. In A549 and H460 non-small cell lung cancer (NSCLC) cells, 1,25-D3 (the hormonally active form of vitamin D) and EB 1089 prolonged the growth arrest induced by radiation alone and suppressed proliferative recovery, which translated to a significant reduction in clonogenic survival. In H838 or H358 NSCLC cells, which lack VDR/vitamin D receptor or functional TP53, respectively, 1,25-D3 failed to modify the extent of radiation-induced growth arrest or suppress proliferative recovery post-irradiation. Sensitization to radiation in H1299 NSCLC cells was evident only when TP53 was induced in otherwise tp53-null H1299 NSCLC cells. Sensitization was not associated with increased DNA damage, decreased DNA repair or an increase in apoptosis, necrosis, or senescence. Instead sensitization appeared to be a consequence of the conversion of the cytoprotective autophagy induced by radiation alone to a novel cytostatic form of autophagy by the combination of 1,25-D3 or EB 1089 with radiation. While both pharmacological and genetic suppression of autophagy or inhibition of AMPK phosphorylation sensitized the NSCLC cells to radiation alone, inhibition of the cytostatic autophagy induced by the combination treatment reversed sensitization. Evidence for selectivity was provided by lack of radiosensitization in normal human bronchial cells and cardiomyocytes. Taken together, these studies have identified a unique cytostatic function of autophagy that appears to be mediated by VDR, TP53, and possibly AMPK in the promotion of an enhanced response to radiation by 1,25-D3 and EB 1089 in NSCLC.
authors: a Department of Pharmacology and Pharmacology; Massey Cancer Center ; Virginia Commonwealth University ; Richmond , VA USA.
authors: Khushboo
authors: K
authors: Sharma
authors: Rachel W
authors: RW
authors: Goehe
authors: Xu
authors: X
authors: Di
authors: Mark Anthony
authors: MA
authors: Hicks
authors: Suzy V
authors: SV
authors: Torti
authors: Frank M
authors: FM
authors: Torti
authors: Hisashi
authors: H
authors: Harada
authors: David A
authors: DA
authors: Gewirtz
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis; D001343:Autophagy / Q000187:drug effects*; D002117:Calcitriol / Q000031:analogs & derivatives* / Q000494:pharmacology; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000532:radiotherapy; D045744:Cell Line, Tumor; D004249:DNA Damage; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000532:radiotherapy; D014807:Vitamin D / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; D014807:Vitamin D; D002117:Calcitriol; C078903:seocalcitol
keywords: ACTB, actin, β; AMPK, AMP activated protein kinase; ANXA5, annexin A5; ATG5, autophagy related 5; AVO, acidic vesicular organelles; BECN1, Beclin 1, autophagy-related; Baf, bafilomycin A1; FACS, fluorescence activating cell sorting; GFP, green fluorescent protein; H2AFX/H2AX, H2A histone family, member X; GLB, galactosidase; MAP1LC3/LC3, microtubule-associated protein 1 light chain 3; NSCLC; NSCLC, non-small cell lung cancer; PI, propidium iodide; SQSTM1, sequestosome 1; TP53, tumor protein p53; VDR, vitamin D (1, 25-dihydroxyvitamin D3) receptor; WT, wild-type; LC3 and LC3-II acronyms have been used to indicate the LC3B and LC3BII isoforms respectively; autophagy; cytoprotective; cytostatic; radiation; β
references: Rheum Dis Clin North Am. 2012 Feb;38(1):161-78
references: 22525850
references: Naunyn Schmiedebergs Arch Pharmacol. 2011 Aug;384(2):209-16
references: 21614555
references: Clin Cancer Res. 2003 Jun;9(6):2350-6
references: 12796405
references: Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7
references: 7568133
references: Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):20364-71
references: 24277826
references: Cancer Res. 2006 Feb 15;66(4):2116-28
references: 16489012
references: Discov Med. 2012 Apr;13(71):287-97
references: 22541616
references: Int J Radiat Biol. 2005 Jun;81(6):445-58
references: 16308915
references: Horm Cancer. 2011 Oct;2(5):272-85
references: 21887591
references: J Surg Oncol. 2012 Nov;106(6):680-8
references: 22674626
references: Oncol Rep. 2011 Apr;25(4):1073-81
references: 21286670
references: Cancer Res. 2000 Aug 15;60(16):4638-44
references: 10969818
references: Best Pract Res Clin Endocrinol Metab. 2011 Aug;25(4):543-59
references: 21872797
references: Cancer Biol Ther. 2013 Nov;14(11):999-1004
references: 24025353
references: Nat Protoc. 2009;4(12):1798-806
references: 20010931
references: Cancer Res. 2007 Apr 1;67(7):3043-53
references: 17409411
references: Radiat Oncol. 2014;9:17
references: 24410971
references: J Biol Chem. 2008 Dec 5;283(49):33911-8
references: 18819919
references: Cell Death Differ. 2014 Jan;21(1):92-9
references: 24037090
references: Front Biosci (Landmark Ed). 2011;16:1693-713
references: 21196257
references: Radiologe. 2008 Sep;48(9):871-80
references: 18709346
references: Nat Rev Mol Cell Biol. 2012 Apr;13(4):251-62
references: 22436748
references: Lung Cancer. 2014 Feb;83(2):117-25
references: 24373738
references: Curr Med Chem Anticancer Agents. 2002 Nov;2(6):683-90
references: 12678720
references: Autophagy. 2012 Feb 1;8(2):236-51
references: 22240589
references: J Natl Cancer Inst. 2001 May 16;93(10):745-53
references: 11353784
references: Annu Rev Pharmacol Toxicol. 2012;52:381-400
references: 22017684
references: Jpn J Radiol. 2012 Apr;30(3):249-54
references: 22311092
references: Mol Endocrinol. 2012 Aug;26(8):1443-54
references: 22700587
references: J Biomed Sci. 2000 Jan-Feb;7(1):64-70
references: 10644891
references: Cell Death Differ. 2011 Oct;18(10):1598-607
references: 21475306
references: Radiat Res. 1999 Nov;152(5):479-86
references: 10521924
references: Anticancer Res. 2006 Jul-Aug;26(4A):2551-6
references: 16886663
references: Cancer Res. 2000 Feb 15;60(4):1009-13
references: 10706117
references: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references: 22237781
references: Cancer Biother Radiopharm. 2013 Mar;28(2):153-9
references: 23268708
references: Expert Rev Respir Med. 2011 Jun;5(3):305-9
references: 21702651
references: Mol Biol Cell. 2009 Apr;20(7):1992-2003
references: 19225151
references: Mol Cancer Ther. 2006 Nov;5(11):2786-97
references: 17121925
references: Br J Cancer. 2013 Oct 29;109(9):2301-8
references: 24091620
references: Lung Cancer. 2012 Aug;77(2):265-71
references: 22564539
references: Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8204-9
references: 15928081
references: Crit Rev Oncol Hematol. 2012 Jul;83(1):130-44
references: 22280915
references: Autophagy. 2012 Apr;8(4):445-544
references: 22966490
references: Biochem Pharmacol. 2008 Oct 15;76(8):947-57
references: 18657518
references: Semin Cancer Biol. 2013 Oct;23(5):361-79
references: 23811268
references: Cancer Chemother Pharmacol. 2003 May;51(5):415-21
references: 12690516
references: Biochem Pharmacol. 2013 Dec 15;86(12):1708-20
references: 24161784
references: Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1104-10
references: 18483332
references: Mol Biol Cell. 2010 Mar 1;21(5):739-52
references: 20053681
references: J Clin Oncol. 2007 Feb 10;25(5):479-85
references: 17290055
references: J Steroid Biochem Mol Biol. 2011 Jan;123(1-2):30-6
references: 20955794
references: Autophagy. 2012 May 1;8(5):739-53
references: 22498493